Journal of Asian Natural Products Research · 2012 · 45 citations · 19 references
MedicineEndocrinologyPharmacologyAutophagyDiabetologyMolecular PharmacologyAutophagy DysregulationAutophagy In DiseaseAutophagy ModulationAutophagy RegulationDiabetes MellitusDiabetes PharmacotherapyAutophagy ImpairmentBlood Glucose RegulationDiabetes Mellitus PathophysiologyPancreatic Islet CellsSirtuin 1 RegulationSirtuin RegulationSirtuin SignalingSystemic Administration
Improper adjustments of autophagy and silent information regulator 1 (Sirt-1) expression were reported to be closely associated with metabolic disorders. In this study, we examined the roles of Sirt-1 and autophagy in streptozotocin-induced diabetes mellitus, assessed the relationship between autophagy and Sirt-1, and investigated the protective mechanism of silibinin. Diabetes was induced in 6-week-old mice by intravenous injection of streptozotocin (150 mg/kg/day, for 2 weeks). In the treatment groups, silibinin (50 mg/kg/day, intramuscular injection, for 8 weeks) or inhibitors (50 mg/kg/day, subcutaneous injection, for 8 weeks) were given. Diabetic control animals received vehicle for the same time. Compared with diabetic controls, silibinin or autophagy inhibitor, 3-methyladenine, treated mice showed decreased levels of glycosylated hemoglobin A1C (P < 0.01), serum triglyceride (P < 0.01), cholesterol (P < 0.01), blood glucose (P < 0.05), autophagy (P < 0.05), and apoptosis ratio (P < 0.05) of pancreatic β-cells. Systemic administration of silibinin reversed streptozotocin-induced downregulation of Sirt-1 expression. Sirt-1 may play a role in regulating the physiological level of autophagy and is associated with loss of pancreatic β-cells and metabolic biochemical disorders. Through promoting Sirt-1 expression and recovering autophagy physiologically, silibinin may reverse hyperglycemia and repair damaged pancreatic β-cells.
19
Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase
Anne Brunet, Lora B. Sweeney, James Fitzhugh Sturgill et al. · Science · 2004 · 3.2K citations
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Jill C. Milne, Philip Lambert, Simon Schenk et al. · Nature · 2007 · 1.7K citations · Full text